Individuals with severe hemophilia A (plasma FVIII levels < 1%, which represent approximately 60% of patients), require replacement of FVIII to levels sufficient for maintaining hemostasis, and reducing the likelihood of joint bleeding and damage (1). Here, F8 is linked to hemophilia A.